Quetiapine augmentation for depression: Dosing pattern in routine practice

International Clinical Psychopharmacology

Volumn 30, Issue 1, 2015, Pages 54-58

  Pae, Chi Un ^a,b   Wang, Sheng Min ^a   Han, Changsu ^c   Lee, Soo Jung ^a   Patkar, Ashwin A ^d   Masand, Prakash S ^d  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Korea University College of Medicine   (South Korea)

^d Global Medical Education Inc   (United States)

Author keywords

Atypical antipsychotics; Augmentation; Doses; Major depressive disorder; Quetiapine

Indexed keywords

AMFEBUTAMONE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; SERTRALINE; TIANEPTINE; VENLAFAXINE; ANTIDEPRESSANT AGENT; DIBENZOTHIAZEPINE DERIVATIVE;

ADULT; ANXIETY DISORDER; ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); DIZZINESS; DYSPEPSIA; ELECTRONIC MEDICAL RECORD; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEALTH CARE PRACTICE; HUMAN; LETHARGY; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; XEROSTOMIA; AGED; CLINICAL PRACTICE; DEPRESSIVE DISORDER, MAJOR; DOSE CALCULATION; DRUG COMBINATION; MIDDLE AGED; PRACTICE GUIDELINE; PSYCHOLOGY; STANDARDS; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DRUG DOSAGE CALCULATIONS; DRUG THERAPY, COMBINATION; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84918780345     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000055     Document Type: Article

References (32)

1. Bauer M, Demyttenaere K, El-Khalili N, Thase ME, Papakostas GI, Szamosi J, et al. (2014). Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive diso rder according to ongoing SSRI or SNRI treatment. Int Clin Psychopharmacol 29:16-25.
2. Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H (2010). A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 127 (1- 3):19-30.
3. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M (2009). Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70:540-549.
4. Carney AC (2013). Efficacy of quetiapine off-label uses: data synthesis. J Psychosoc Nurs Ment Health Serv 51:11-18.
5. Chaput Y, Magnan A, Gendron A (2008). The co-adm inistration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. BMC Psychiatry 8:73.
6. Chen SJ, Hsiao YL, Shen TW, Chen ST (2012). The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial. J Clin Psychopharmacol 32:56-60.
7. Chowbay B, Zhou S, Lee EJ (2005). An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab Rev 37:327-378.
8. Coe HV,Hong IS, 2012, Safety of low doses of quetiapine when used for insomnia,Ann Pharmacother, 46, 718-722.
9. El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H (2010). Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-cont rolled study. Int J Neuropsychopharmacol 13:917-932.
10. Eriksson L, Hallerbä ck T, Jørgensen L, Carlborg A (2012). Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schiz ophrenia: a retrospective study. Ther Adv Psychopharmacol 2:217-226.
11. Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J (2008). A randomized, double-blind, and pla cebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 23:269-275.
12. Han C, Pae CU (2013). Do we need to consider ethno-cultural variation in the use of atypical antipsychotics for Asian patients with major depressive disorder? CNS Drugs 27 (Suppl 1):S47-S51.
13. Han C, Wang SM, Kato M, Lee SJ, Patkar AA, Masand PS, Pae CU (2013). Second-generation antipsycho tics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother 13:851-870.
14. Hartung DM, Wisdom JP, Pollack DA, Hamer AM, Haxby DG, Middleton L, McFarland BH (2008 ). Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. J Clin Psychiatry 69:1540-1547.
15. Jing Y, Guo Z, Kalsekar I, Forbes RA, Hebden T, Thase ME (2013). Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010). Int Clin Psychopharmacol 28:87-90.
16. Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, et al. ADMIRE Study Group (2013). Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). J Affect Disord 151:899 -905.
17. Lin CH, Lin SH, Jang FL (2011). Adjunctive low-dose aripiprazole with standarddose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. J Clin Psychopharmacol 31:563-568.
18. Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, et al. (2011). Off-label use of atypical antipsychotics: an update. Rockville, MD: Agency for Healthcare Research and Qualit y.
19. Marks DM, Thanaseelan J, Pae CU (2009). Innovations in clinical research design and conduct in psychiatry: shifting to pragmatic approaches. Psychiatry Investig 6:1-6.
20. Martin K, Benta berry F, Dumoulin C, Dehais J, Haramburu F, Bé gaud B, Schaeverbeke T (2005). Effectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials. Clin Exp Rheumatol 2 3:80-84.
21. McIntyre A, Gendron A, McIntyre A (2007). Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebocon trolled pilot study. Depress Anxiety 24:487-494.
22. Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, et al. (2012). Efficacy of dose increase among nonresponders to low-dose aripipra zole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry 73:353-357.
23. Nelson JC, Papakostas GI (2009). Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166:980-991.
24. Pae CU, Bodkin JA, Portland KB, Thase ME, Patkar AA (2 012). Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures. J Clin Psychiatry 73:661-668.
25. Pae CU, Forbes A, Patkar AA (2011). Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 25:109-127.
26. Pae CU, Jeon HJ, Lee BC, Seo HJ, Kim SG, Park EJ, et al. (2013). Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study. Int Clin Psychopharmacol 28:322-329.
27. Pae CU, Patkar AA ( 2013). Clinical issues in use of atypical antipsychotics for depressed patients. CNS Drugs 27 (Suppl 1):S39-S45.
28. Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS (2014). Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting. Int Clin Psychopharmacol 29:116-119.
29. Patkar AA, Pae CU (2013). Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs 27 (Suppl 1):S29-S37.
30. Vancampfort D,Correll CUWampers M,Sienaert P,Mitchell AJ,de Herdt A,et al. (2013), Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables, Psychol Med, 21,1-12.
31. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriks son H. Moonstone Study Group (2009). Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebocontrolled study. CNS Spectr 14:299-313.
32. Wen XJ , Wang LM, Liu ZL, Huang A, Liu YY, Hu JY (2014). Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder. Braz J Med Biol Res 47:605-616.